权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Role of Cancer-Associated Fibroblasts in Cholangiocarcinoma

癌症相关成纤维细胞在胆管癌中的作用

基本信息

批准号：
10414782
负责人：
Xin Chen
金额：
$ 60.91万
依托单位：
COLUMBIA UNIVERSITY HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-06-19 至 2024-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10414782
关键词：
Ablation Affect Apoptotic Blocking Antibodies Cell Compartmentation Cell Death Cell Proliferation Cells Characteristics Cholangiocarcinoma Clinical Clinical Research Coculture Techniques Collagen Collagen Receptors Desmoplastic Development Drug usage Extracellular Matrix FDA approved Family Fibroblasts Fibrosis Gene Expression Genes Goals Growth Human In Vitro Incidence Injections Integrins Interruption Intrahepatic Cholangiocarcinoma Knock-out Knockout Mice Light Link Liver Liver neoplasms Malignant Neoplasms Malignant neoplasm of pancreas Measures Mediating Mediator of activation protein Mus Myofibroblast Nature Outcome Pancreas Pathway interactions Pharmaceutical Preparations Pharmacology Platelet-Derived Growth Factor Primary Malignant Neoplasm of Liver Protein Isoforms Role Sampling Signal Pathway Signal Transduction Survival Rate System Testing Therapeutic Time Tumor Promoters Tumor Promotion Tumor-Derived cancer genetics conventional therapy discoidin domain receptor 1 discoidin receptor experimental study genetic approach in vivo inhibiting antibody innovation interest intrahepatic liver injury migration neoplastic cell new therapeutic target nintedanib novel novel therapeutic intervention recruit single cell sequencing single-cell RNA sequencing tool tumor tumor microenvironment

项目摘要

Intrahepatic cholangiocarcinoma (ICC) is an aggressive liver tumor with limited therapeutic options and 5-year survival rates of less than 10%. ICC is characterized by its highly desmoplastic nature, with abundance of cancer- associated fibroblasts (CAF) and extracellular matrix (ECM). The role of CAF and ECM in ICC remain controversial due to the paucity of functional in vivo studies. While the majority of ICC in vitro studies support a cancer-promoting role of CAF, recent studies in endogenously arising pancreatic cancer, a highly desmoplastic tumor with many similarities to ICC, have shown that CAF restrain cancer growth. Here, we seek to answer the question whether CAF promote or restrain ICC, using a number of novel and cell-specific tools to manipulate CAF and tumor cells and their crosstalk in endogenously arising ICC in vivo. We hypothesize that CAF and ECM provide a niche that promotes ICC growth and survival, and that detailed characterization of ICC-CAF crosstalk will identify novel therapeutic targets within the tumor microenvironment. In Aim 1, we will determine the role CAF using novel tools to determine how genetic CAF inhibition or early and late CAF ablation affect ICC growth, proliferative and anti-apoptotic signaling pathways, and mouse survival. In Aim 2, we will investigate pathways that mediate the recruitment, proliferation and activation of CAF in ICC focusing on the hypothesis that tumor cells hijack normal fibrogenic mechanism in the liver via tumor-derived TGFb and PDGF isoforms and TGFb- activating integrins, resulting in accumulation and activation of CAF. In addition to detailed mechanistic studies in knockout mice and in vitro co-cultures, we will determine whether pharmacologic inhibition of CAF activation by FDA-approved drug Nintedanib or integrin-blocking antibodies inhibit ICC growth and prolong mouse survival. In Aim 3, we will determine pathways through which CAF modulate ICC growth, focusing on the hypothesis that CAF-derived ECM activates tumor-promoting signals in the tumor cell compartment. To test this hypothesis, we will investigate ICC development in mice with CAF-specific knockout of Col1a1, or tumor-selective knockout of collagen-sensing receptor discoidin domain receptor 1 (DDR1). In addition, we will determine whether ECM- mediated stiffness and subsequent activation of mechanosensitive signaling in tumor cells promote ICC development. We will measure tumor stiffness, activation of mechanosensitive signaling pathways and DDR1 expression in human CCA samples and correlate these to clinical outcomes. The role of stiffness and DDR1 in ICC growth and CAF-ICC crosstalk will be investigated in more detail in vitro through modulation of stiffness and by co-culturing CAF and ICC cells that lack Col1a1 or DDR1, respectively. In summary, the proposed studies will employ novel tools to answer a long-standing question in the field and may provide a basis for targeting ICC- CAF crosstalk as novel therapeutic strategy for this devastating malignancy.

肝内胆管细胞癌（ICC）是一种侵袭性肝脏肿瘤，治疗选择有限， ICC的特征是其高度促纤维增生的性质，相关成纤维细胞（CAF）和细胞外基质（ECM）在ICC中的作用仍然存在。由于缺乏体内功能性研究，这一点存在争议。尽管大多数体外ICC研究支持 CAF的促癌作用，最近对内源性胰腺癌的研究，高度促结缔组织增生肿瘤与ICC有许多相似之处，已经表明CAF抑制癌症生长。在这里，我们试图回答使用一些新的和细胞特异性的工具来操纵CAF是否促进或抑制ICC， CAF和肿瘤细胞以及它们在体内内源性ICC中的相互作用。提供了一个促进ICC生长和存活的利基，以及ICC-微通道CAF串扰的详细表征，将在肿瘤微环境中识别新的治疗靶点。在目标1中，我们将确定 CAF使用新的工具来确定遗传CAF抑制或早期和晚期CAF消融如何影响ICC生长，在目标2中，我们将研究细胞增殖和抗凋亡信号通路，在ICC中介导CAF的募集、增殖和活化，细胞通过肿瘤源性TGFb和PDGF亚型以及TGFb-劫持肝脏中正常的纤维化机制激活整合素，导致CAF的积累和激活。在基因敲除小鼠和体外共培养中，我们将确定药物抑制CAF活化是否通过FDA批准的药物Neptin或整合素受体阻断抗体抑制ICC的生长并延长小鼠的存活时间。在目标3中，我们将确定CAF调节ICC生长的途径，重点是假设 CAF衍生的ECM激活肿瘤细胞区室中的肿瘤促进信号。为了验证这个假设，我们将研究在CAF特异性敲除Col 1a 1或肿瘤选择性敲除胶原敏感受体盘状结构域受体1（DDR 1）。此外，我们将确定ECM是否- 肿瘤细胞中介导的僵硬和随后的机械敏感信号传导激活促进ICC 发展我们将测量肿瘤硬度，机械敏感信号通路的激活和DDR 1 在人CCA样品中的表达，并将这些与临床结果相关联。刚度和DDR 1在 ICC生长和CAF-ICC串扰将在体外通过刚度的调制和通过分别共培养缺乏Col 1a 1或DDR 1的CAF和ICC细胞。总之，拟议的研究将采用新的工具来回答该领域长期存在的问题，并可能为针对ICC-2000提供基础 CAF串扰作为这种毁灭性恶性肿瘤的新治疗策略。